1 story in the last 7 days
The latest disc medicine news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks disc medicine across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) over allegations of misleading business information. The FDA issued a Complete Response Letter on February 13, 2026, declining to approve Disc Medicine's bitopertin drug application due to uncertainties. Disc Medicine's stock price fell 22% that day.
Summaries by ByteBrief